Drug manufacturer Strativa Pharmaceuticals (the proprietary products division of Par Pharmaceutical Companies, Inc.) recently announced that preliminary data from a clinical trial of a drug developed for the treatment of mesothelioma, ONCONASE (ranpirnase), showed mixed results. Strativa is working on the drug with its development partner, Alfacell Corporation. The clinical trial studied survival rates of patients treated with both ONCONASE and doxorubicin as compared to patients who were treat
Tuesday, June 17, 2008
Subscribe to:
Post Comments (Atom)
Subscribe To
Posts
Comments
No comments:
Post a Comment